The POISE randomized double-blind placebo-controlled trial demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes (ALP, bilirubin, AST, ALT) in patients with primary biliary cholangitis (PBC). The objective of this study was to evaluate time to first occurrence of liver transplant or death in OCA-treated patients in the POISE trial and open label extension versus comparable non-OCA-treated external controls.
Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Cazzagon, Nora;Floreani, Annarosa;
2022
Abstract
The POISE randomized double-blind placebo-controlled trial demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes (ALP, bilirubin, AST, ALT) in patients with primary biliary cholangitis (PBC). The objective of this study was to evaluate time to first occurrence of liver transplant or death in OCA-treated patients in the POISE trial and open label extension versus comparable non-OCA-treated external controls.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0016508522010605-main.pdf
accesso aperto
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Creative commons
Dimensione
2.13 MB
Formato
Adobe PDF
|
2.13 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
